review
remark
author
merssard
deadli
coronavirus
current
antivir
vaccin
avail
thu
studi
iidentif
small
lipid
activ
molecul
broad
inhibitori
activ
varieti
virus
whose
replic
lipid
depend
import
time
one
effect
dose
small
molecul
appear
well
dose
cytotox
vivo
data
mice
also
quit
promis
collect
excit
find
worthi
public
pursuit
one
issu
whether
mechan
action
realli
srebp
sirna
knockdown
show
log
decreas
viral
copi
number
wherea
infect
mice
treat
molecul
appear
cure
author
tri
doubl
knock
crispr
review
remark
author
summari
manuscript
author
use
transcriptom
lipidom
merscov
infect
cell
identifi
alter
cellular
lipid
metabol
screen
bioactiv
lipid
librari
identifi
lipid
broad
spectrum
antivir
activ
vitro
vivo
character
compound
suggest
target
nsrebp
common
node
viral
infect
dock
bind
studi
lend
support
interact
impact
lipid
biosynthesi
show
role
inhibit
fatti
acid
synthesi
fa
particular
gener
support
manuscript
although
srebpfa
pathway
implic
viral
manipul
broadspectrum
drug
target
previou
studi
identif
bioactiv
lipid
inhibitor
efficaci
vitro
vivo
plu
good
select
index
quit
interest
experi
lack
control
mani
overinterpret
need
address
revis
specif
point
mention
mani
studi
identifi
srebpfa
viral
manipul
inhibit
inhibit
viral
replic
includ
virus
studi
iav
flavivirus
referenc
discuss
fig
transcriptomiclipidom
analysi
done
cancer
cell
line
alreadi
deregul
metabol
caveat
need
mention
abstract
mislead
suggest
use
unbias
click
approach
identifi
srebp
fact
use
heavili
bias
candid
approach
investig
srebp
abstract
need
edit
accuraci
better
perform
clickm
proteom
approach
see
bind
unbias
fashion
fig
f
differ
overli
impress
perform
statist
analysi
indic
signific
differ
time
prior
sacrific
fig
fig
issu
control
interpret
clear
whether
phenotyp
result
directli
inhibit
cellular
process
indirectli
inhibit
viral
review
remark
author
replic
instanc
affect
lipid
droplet
ld
accumul
directli
less
viral
enhanc
ld
less
viral
replic
dmv
direct
role
dmv
format
replic
inhibit
way
around
issu
creat
cell
line
express
viral
proteinspolyprotein
respons
alter
express
unaffect
drug
approach
use
extens
relat
viru
field
author
could
also
investig
uninfect
cell
cell
induc
lipid
metabol
via
mean
current
data
way
overinterpret
issu
includ
lack
rnai
specif
control
multipl
distinct
sirna
prefer
express
sirna
resist
srebp
fig
also
overinterpret
starvat
induc
srebp
induc
autophagi
experi
need
remov
replac
srebp
overexpress
fig
lack
vehicl
usual
dmso
control
cell
viabil
control
fig
two
issu
smaller
one
paltim
graph
legend
second
less
palmitoyl
ha
mean
infect
inhibit
lipid
downstream
palmit
may
import
complement
experi
also
includ
downstream
lipid
oleic
acid
model
correct
oleic
acid
complement
rna
virus
iav
review
remark
author
paper
present
data
viral
infect
alter
lipidom
profil
host
cell
synthet
retino
acid
receptor
agonist
interrupt
viru
life
cycl
also
demonstr
select
bind
sterol
regulatori
element
bind
protein
srebp
author
show
heatmap
lipid
purportedli
chang
viral
infect
detail
method
identif
lipid
extrem
sketchi
evalu
analyt
methodolog
exampl
lipid
identifi
neither
descript
identif
refer
method
lipid
presum
extract
standard
blighdyer
method
extract
analyz
lcm
procedur
author
describ
reconstitut
dri
lipid
extract
chloroformmethanol
inject
directli
lcm
initi
mobil
phase
condit
essenti
consist
water
contain
acetonitril
acet
acid
flow
rate
mlmin
despit
presenc
methanol
sampl
sampl
immisc
mobil
phase
flow
rate
abl
perform
chromatographi
mention
intern
standard
use
lcm
lipid
quantifi
ascertain
chang
upon
infect
lipid
identifi
figur
conform
standard
nomenclatur
key
supplement
data
identifi
lipid
detail
need
evalu
method
result
present
abl
inhibit
viru
replic
treatment
viru
infect
cell
restor
lipidom
profil
link
abil
inhibit
viru
replic
lipidom
profil
chang
circumstanti
best
data
present
screen
commerci
lipid
librari
inhibit
viru
replic
enhanc
cell
viabil
least
two
compound
either
equal
better
lipid
also
bind
srebp
inhibit
viru
replic
despit
liber
use
term
bioactiv
lipid
author
endogen
natur
occur
bioactiv
lipid
synthet
agonist
presum
could
compound
lipid
librari
synthet
call
bioactiv
lipid
mislead
lack
understand
bioactiv
lipid
review
remark
author
manuscript
yuan
et
al
describ
identif
sterol
regulatori
element
bind
protein
srebp
key
regul
lipid
biosynthesi
potenti
cellular
target
antivir
therapeut
author
use
transcriptom
lipidom
profil
well
multipl
molecular
biochem
method
show
proteolyt
process
lipid
biosynthesi
pathway
includ
palmitoyl
doublemembran
vesicl
format
affect
srebp
latter
known
essenti
viru
replic
particl
format
author
found
previous
establish
compound
block
srebp
bind
sterol
regulatori
element
sre
treatment
post
infect
inhibit
viru
replic
vitro
merscov
sarscov
zikv
vivo
mous
model
merscov
influenza
viru
author
therefor
claim
identifi
broadspectrum
antivir
drug
manuscript
overal
concis
well
written
data
gener
support
vitro
vivo
data
identif
key
regul
lipid
biosynthesi
interest
particular
virus
exploit
pathway
sequest
byproduct
viru
replic
dsrna
immun
recognit
produc
viru
progeni
howev
claim
identifi
broadact
antivir
therapeut
opinion
exagger
neither
appli
organoid
intestin
model
rel
artifici
transgen
mous
model
justifi
titl
paper
ie
target
srebpdepend
lipidom
reprogram
viru
infect
broadspectrum
therapeut
intervent
importantli
offtarget
downstream
effect
result
treatment
investig
particular
lack
dmv
format
may
affect
innat
immun
regul
supplementari
figur
suffici
exclud
affect
immun
regul
context
merscov
replic
major
figur
author
provid
pfuml
viru
genom
equivalentsml
either
main
figur
least
supplement
inform
block
dmv
format
one
would
expect
increas
defect
interf
particl
compound
inhibit
dmv
format
like
result
increas
exposur
merscovderiv
dsrna
cellular
helicas
subsequ
activ
interferon
pathway
pleas
includ
experi
use
viru
infect
treatment
follow
assess
immun
activ
exampl
real
time
pcr
ifn
elisa
merssard
deadli
coronavirus
current
antivir
vaccin
avail
thu
studi
identif
small
lipid
activ
molecul
broad
inhibitori
activ
varieti
virus
whose
replic
lipid
depend
import
time
one
effect
dose
small
molecul
appear
well
dose
cytotox
vivo
data
mice
also
quit
promis
collect
excit
find
worthi
public
pursuit
one
issu
whether
mechan
action
realli
srebp
sirna
knockdown
show
log
decreas
viral
copi
number
wherea
infect
mice
treat
molecul
appear
cure
author
tri
doubl
knock
crispr
respons
thank
insight
comment
review
agre
review
knockdown
exhibit
similar
level
antivir
potenc
might
due
mutual
compens
either
one
protein
impair
shimano
et
al
sred
dnabind
activ
block
additionalsynergist
antivir
effect
support
observ
doubl
knockdown
addit
experi
result
log
decreas
infecti
viru
particl
compar
log
reduct
individu
knockdown
togeth
comment
review
regard
rnai
specif
includ
experi
use
distinct
sirna
target
ie
ie
result
includ
line
page
tri
crispr
knockout
either
appear
detriment
host
cell
might
due
essenti
cellular
function
srebp
pathway
line
other
report
defici
lethal
utero
knockout
mice
defici
lethal
embryogenesi
horton
goldstein
brown
summari
manuscript
author
use
transcriptom
lipidom
merscov
infect
cell
identifi
alter
cellular
lipid
metabol
screen
bioactiv
lipid
librari
identifi
lipid
broad
spectrum
antivir
activ
vitro
vivo
character
compound
suggest
target
nsrebp
common
node
viral
infect
dock
bind
studi
lend
support
interact
impact
lipid
biosynthesi
show
role
inhibit
fatti
acid
synthesi
fa
particular
gener
support
manuscript
although
srebpfa
pathway
implic
viral
manipul
broadspectrum
drug
target
previou
studi
identif
bioactiv
lipid
inhibitor
efficaci
vitro
vivo
plu
good
select
index
quit
interest
experi
lack
control
mani
overinterpret
need
address
revis
mention
mani
studi
identifi
srebpfa
viral
manipul
inhibit
inhibit
viral
replic
includ
virus
studi
iav
flavivirus
referenc
discuss
respons
thank
help
comment
review
agre
review
includ
follow
paragraph
line
page
discuss
section
import
srebp
regulatori
pathway
implic
life
cycl
hantaviru
depend
lipid
synthesi
viru
entri
membran
fusion
process
kleinfelt
et
al
petersen
et
al
also
exemplifi
pharmacolog
inhibit
fa
cerulenin
impair
replic
broadspectrum
virus
specif
human
cytomegaloviru
influenza
viru
infect
may
requir
fatti
acid
synthesi
modul
membran
composit
viral
bud
protein
modif
munger
et
al
direct
inhibit
fa
reduc
infect
respiratori
syncyti
viru
human
rhinoviru
serotyp
chang
membran
compon
virion
progeni
particl
denv
recruit
fa
site
replic
stimul
fatti
acid
synthesi
heaton
et
al
fig
transcriptomiclipidom
analysi
done
cancer
cell
line
alreadi
deregul
metabol
caveat
need
mention
respons
agre
review
includ
comment
discuss
line
page
similar
studi
use
cancer
cell
line
usual
underw
complex
genet
metabol
rearrang
may
affect
interpret
result
kaur
dufour
abstract
mislead
suggest
use
unbias
click
approach
identifi
srebp
fact
use
heavili
bias
candid
approach
investig
srebp
abstract
need
edit
accuraci
better
perform
clickm
proteom
approach
see
bind
unbias
fashion
respons
agre
review
made
clarif
accordingli
pleas
refer
page
line
use
click
chemistri
overexpress
sterol
regulatori
element
bind
protein
srebp
shown
interact
account
broadspectrum
antivir
activ
fig
f
differ
overli
impress
perform
statist
analysi
indic
signific
differ
time
prior
sacrific
respons
address
review
comment
addit
mice
experi
done
method
statist
analysi
modifi
new
show
mice
group
exhibit
significantli
higher
bodi
weight
p
dmsotreat
group
day
postinfect
merscov
infect
mice
term
influenza
mous
model
new
mice
show
less
bodi
weight
loss
dmsotreat
group
day
day
postinfect
current
surviv
rate
bodi
weight
result
merscov
infect
model
pool
previou
round
addit
round
manuscript
revis
statist
transform
bodi
weight
chang
individu
mous
follow
mean
sd
calcul
day
postinfect
previou
version
manuscript
calcul
mean
sd
valu
mice
day
first
follow
transform
believ
new
approach
data
analysi
reason
revis
descript
result
page
line
line
updat
method
page
accordingli
fig
issu
control
interpret
clear
whether
phenotyp
result
directli
inhibit
cellular
process
indirectli
inhibit
viral
replic
instanc
affect
lipid
droplet
ld
accumul
directli
less
viral
enhanc
ld
less
viral
replic
dmv
direct
role
dmv
format
replic
inhibit
way
around
issu
creat
cell
line
express
viral
proteinspolyprotein
respons
alter
express
unaffect
drug
approach
use
extens
relat
viru
field
author
could
also
investig
uninfect
cell
cell
induc
lipid
metabol
via
mean
current
data
way
overinterpret
respons
agre
review
comment
one
recent
public
clearli
demonstr
coexpress
merscov
suffici
induc
dmv
format
oudshoorn
et
al
therefor
use
treat
cell
cotransfect
hour
signific
chang
detect
express
level
viral
protein
find
indic
reduc
dmv
format
caus
inhibit
lipid
accumul
directli
inhibit
viral
replic
indirectli
ad
set
result
line
new
manuscript
issu
includ
lack
rnai
specif
control
multipl
distinct
sirna
prefer
express
sirna
resist
srebp
fig
also
overinterpret
starvat
induc
srebp
induc
autophagi
experi
need
remov
replac
srebp
overexpress
respons
address
issu
rnai
specif
purchas
distinct
sirna
target
ie
togeth
comment
review
also
demonstr
doubleknockdown
caus
less
viru
replic
compar
knockdown
alon
pleas
refer
legend
page
line
new
fig
detail
term
overexpress
perform
assay
accordingli
show
new
overexpress
diminish
antivir
potenc
pleas
refer
result
descript
page
line
legend
page
line
detail
fig
two
issu
smaller
one
paltim
graph
legend
second
less
palmitoyl
ha
mean
infect
inhibit
lipid
downstream
palmit
may
import
complement
experi
also
includ
downstream
lipid
oleic
acid
model
correct
oleic
acid
complement
rna
virus
iav
respons
apolog
typo
revis
palmit
accordingli
also
includ
oleic
acid
complement
assay
demonstr
inabl
fatti
acid
metabolit
rescu
influenza
viru
replic
suggest
reduc
influenza
hemagglutinin
palmitoyl
mainli
account
antivir
activ
pleas
refer
new
paper
present
data
viral
infect
alter
lipidom
profil
host
cell
synthet
retino
acid
receptor
agonist
interrupt
viru
life
cycl
also
demonstr
select
bind
sterol
regulatori
element
bind
protein
srebp
author
show
heatmap
lipid
purportedli
chang
viral
infect
detail
method
identif
lipid
extrem
sketchi
evalu
analyt
methodolog
exampl
lipid
identifi
neither
descript
identif
refer
method
lipid
presum
extract
standard
blighdyer
method
extract
analyz
lcm
procedur
author
describ
reconstitut
dri
lipid
extract
chloroformmethanol
inject
directli
lcm
initi
mobil
phase
condit
essenti
consist
water
contain
acetonitril
acet
acid
flow
rate
mlmin
despit
presenc
methanol
sampl
sampl
immisc
mobil
phase
flow
rate
abl
perform
chromatographi
mention
intern
standard
use
lcm
lipid
quantifi
ascertain
chang
upon
infect
lipid
identifi
figur
conform
standard
nomenclatur
key
supplement
data
identifi
lipid
detail
need
evalu
method
result
present
respons
thank
review
use
comment
fulli
address
review
concern
divid
comment
sever
subquest
lipid
identifi
neither
descript
identif
refer
method
lipid
presum
extract
standard
blighdyer
method
extract
analyz
lcm
respons
apolog
sketchi
methodolog
provid
previou
version
manuscript
tri
reduc
number
word
updat
manuscript
includ
detail
lipidom
methodolog
data
analysi
heatmap
analysi
follow
chemic
reagent
liquid
chromatographymass
spectrometri
lcm
grade
water
methanol
acetonitril
purchas
jt
baker
center
valley
pa
usa
hplcgrade
chloroform
purchas
merck
darmstadt
germani
analyt
grade
acet
acid
commerci
standard
use
biomark
identif
purchas
sigmaaldrich
mo
usa
intern
standard
includ
arachidon
lysoplateletactiv
factor
paf
purchas
cayman
cayman
chemic
usa
sampl
prepar
sampl
prepar
perform
minor
modif
accord
mplex
method
burnumjohnson
et
al
nakayasu
et
al
medium
remov
infect
cell
cell
immedi
wash
twice
icecool
quench
buffer
consist
methanol
ammonium
bicarbon
water
remov
quench
buffer
icecold
ammonium
bicarbon
solut
ad
dissoci
cell
cell
scrape
transfer
tube
nunc
thermo
fisher
usa
ice
cell
suspens
remov
dna
extract
perform
cell
count
normal
genom
dna
minikit
qiagen
germani
use
dna
extract
lipid
extract
solut
chloroformmethanol
vv
contain
ad
tube
aliquot
mix
solut
remov
confirm
steril
infect
assay
lipid
extract
remain
solut
centrifug
bottom
phase
transfer
glass
vial
vial
remov
bsc
bsl
contain
laboratori
appropri
disinfect
dri
vacuum
concentr
dri
sampl
reconstitut
solvent
mixtur
contain
chloroformmethanol
vv
centrifug
supernat
transfer
lc
vial
lcm
analysi
uplcesiqtofm
analysi
cell
lipid
extract
analyz
use
acquiti
uplc
system
coupl
synapt
mass
spectromet
system
water
corp
usa
chromatographi
perform
water
acquiti
beh
column
id
water
milford
usa
mobil
phase
consist
acet
acid
water
b
acetonitril
separ
perform
flow
rate
mlmin
gradient
program
follow
b
b
b
b
b
b
order
achiev
rapid
equival
flow
rate
chang
subsequ
gradient
program
appli
follow
b
b
b
column
autosampl
temperatur
maintain
respect
inject
volum
mass
spectral
data
acquir
posit
neg
mode
capillari
voltag
sampl
cone
voltag
sourc
offset
maintain
respect
nitrogen
use
desolv
ga
flow
rate
lh
sourc
desolv
temperatur
maintain
respect
mass
spectra
acquir
mz
rang
synapt
hdm
system
calibr
use
sodium
format
cluster
oper
sensit
mode
leucin
enkephalin
use
lock
mass
experi
ms
data
acquir
mode
ms
e
lipid
profil
msm
acquisit
oper
paramet
ms
acquisit
lipid
identif
collis
energi
use
rang
ev
fragment
allow
put
identif
structur
elucid
signific
lipid
data
process
statist
data
analysi
acquisit
raw
data
perform
use
masslynx
softwar
version
water
corp
usa
raw
data
firstli
convert
analysi
base
file
abf
format
convert
data
subsequ
deconvolv
mass
featur
mf
list
use
msdial
softwar
http
primepscrikenjp
kind
et
al
tsugawa
et
al
process
data
export
text
file
statist
analysi
total
ion
intens
mf
msdial
report
file
sampl
normal
correspond
dna
concentr
calibr
cell
count
variat
silva
et
al
metaboanalyst
http
wwwmetaboanalystca
use
univari
multivari
statist
analysi
normal
mf
subject
pareto
scale
method
chong
et
al
univari
analysi
statist
signific
featur
determin
among
mockinfect
merscov
infect
merscov
infect
group
use
student
ttest
respect
p
valu
consid
statist
signific
featur
multivari
analysi
orthogon
partial
least
squar
discrimin
analysi
oplsda
perform
supervis
method
find
import
variabl
discrimin
power
model
evalu
relev
protocol
lipid
identif
carri
accord
publish
procedur
tsugawa
et
al
zhu
et
al
statist
signific
featur
given
annot
name
msdial
ms
featur
could
match
intern
librari
criterion
mf
signific
abund
select
msm
experi
analysi
put
lipid
identifi
use
exact
molecular
weight
nitrogen
rule
fragment
literaturedatabas
search
includ
metlin
databas
http
metlinscrippsedu
human
metabolom
databas
http
wwwhmdbca
lipidmap
http
wwwlipidmapsorg
kegg
databas
http
wwwgenomejpkegg
final
confirm
lipid
ident
use
authent
chemic
standard
msm
fragment
pattern
chemic
standard
compar
candid
lipid
lcm
condit
current
compar
lipidom
studi
focu
identifi
significantli
chang
lipid
among
tabl
number
unknown
featur
exhibit
signific
cellular
level
chang
could
identifi
report
preliminari
identifi
lipid
least
match
accur
mass
msdial
intern
databas
lipid
perform
msm
fragment
avail
fragment
pattern
report
websit
databas
diagnost
fragment
pattern
avail
lipid
could
fulli
identifi
thu
label
ms
mean
match
accur
mass
msdial
intern
databas
websit
databas
fa
fahfa
mgdg
moreov
sphingolipid
glycerophospholipid
number
acyl
chain
carbon
doubl
bond
could
determin
label
total
number
carbon
doubl
bond
sm
pe
updat
experiment
detail
methodolog
page
pleas
also
refer
supplementari
tabl
detail
result
supplementari
inform
page
procedur
author
describ
reconstitut
dri
lipid
extract
chloroformmethanol
inject
directli
lcm
initi
mobil
phase
condit
essenti
consist
water
contain
acetonitril
acet
acid
flow
rate
mlmin
despit
presenc
methanol
sampl
sampl
immisc
mobil
phase
flow
rate
abl
perform
chromatographi
respons
thank
review
expert
comment
note
lc
gradient
mobil
phase
composit
optim
cover
lipid
class
even
though
use
mix
solut
consist
chloroformmethanol
lipid
extract
current
lc
protocol
design
analysi
polar
lipid
base
lipidmap
http
wwwlipidmapsorg
method
modif
abl
detect
larg
number
lipid
mass
featur
includ
fatti
acid
glycerophospholipid
sphingomyelin
infect
noninfect
cell
sampl
even
patient
sampl
previou
studi
use
methodolog
lau
et
al
k
k
w
et
al
importantli
intracellular
membran
mainli
consist
glycerophospholipid
play
import
role
signal
viral
replic
cycl
current
studi
focus
glycerophospholipid
chang
base
previous
establish
lipidom
approach
sinc
acetonitril
dissolv
wide
rang
ionic
nonpolar
compound
progress
increas
acetonitril
content
mobil
phase
present
lcgradient
could
provid
good
separ
target
lipid
class
exampl
significantli
chang
lipid
featur
display
supplementari
tabl
shown
differ
type
fatti
acid
glycerophospholipid
sphingomyelin
success
separ
present
lcgradient
elut
differ
retent
time
figur
show
xic
curv
repres
lipid
featur
present
studi
extractedion
chromatogram
xic
curv
repres
lipid
featur
mockuninfect
infectionmerscov
infect
sampl
repres
retent
time
target
peak
xic
mention
intern
standard
use
lcm
respons
use
deuter
lipid
includ
arachidon
lysoplateletactiv
factor
paf
intern
standard
present
studi
known
concentr
intern
standard
ad
lipid
extract
solut
monitor
prepar
variat
shown
tabl
present
manuscript
base
rel
ion
count
intens
comparison
gener
compar
lipidom
experi
thu
reliabl
long
sampl
prepar
data
analysi
nt
signific
system
variat
current
compar
lipidom
studi
use
blank
sampl
intern
standard
dna
quantif
qualiti
control
qc
sampl
perform
parallel
lipid
analysi
lcm
experi
monitor
calibr
analyt
instrument
data
variat
qualiti
blank
sampl
cell
free
sampl
subject
prepar
protocol
aim
remov
fals
posit
featur
nois
signal
mass
featur
list
intern
standard
use
monitor
lipid
extract
variat
differ
sampl
dna
concentr
quantif
perform
sampl
normal
cell
count
variat
qc
sampl
pool
sampl
true
sampl
analyz
batch
queue
true
sampl
ensur
ms
signal
stabl
throughout
analyt
batch
addit
cv
valu
mass
featur
qc
sampl
calcul
evalu
stabil
analyt
batch
result
indic
featur
measur
neg
mode
featur
measur
posit
mode
cv
valu
lower
could
reveal
lipid
analyt
batch
stabl
accept
variat
lipid
identifi
figur
conform
standard
nomenclatur
key
supplement
data
identifi
lipid
respons
apolog
use
improp
lipid
nomenclatur
shown
origin
gener
heatmap
tool
metaboanalyst
updat
lipid
name
figur
base
lipidmap
nomenclatur
http
wwwlipidmapsorg
detail
inform
lipid
name
annot
also
shown
supplementari
tabl
abl
inhibit
viru
replic
treatment
viru
infect
cell
restor
lipidom
profil
link
abil
inhibit
viru
replic
lipidom
profil
chang
circumstanti
best
respons
mani
thank
review
comment
clearli
shown
studi
inhibit
viru
replic
log
reduct
viru
plaqu
form
unit
viral
load
decreas
nucleoprotein
express
western
blot
flow
cytometri
viru
inhibitori
effect
also
shown
mani
virus
multicycl
replic
assay
effect
concentr
level
high
select
index
averag
fig
fig
furthermor
cure
mice
infect
lethal
dose
mer
coronaviru
influenza
viru
mous
model
shown
supplementari
tabl
lipid
significantli
chang
includ
upand
downregul
merscov
infect
chang
lipid
restor
variou
extent
treatment
thu
link
abil
inhibit
viru
replic
associ
lipidom
profil
chang
unlik
circumstanti
data
present
screen
commerci
lipid
librari
inhibit
viru
replic
enhanc
cell
viabil
least
two
compound
either
equal
better
lipid
also
bind
srebp
inhibit
viru
replic
respons
thank
review
insight
observ
first
compound
show
almost
equallygood
protect
merscov
infect
cell
cultur
black
dot
second
compound
aryl
hydrocarbon
receptor
agonist
ficz
exhibit
activ
alreadi
mention
manuscript
page
line
select
studi
broadspectrum
antivir
activ
mer
coronaviru
influenza
viru
aryl
hydrocarbon
receptor
agonist
ficz
exhibit
broad
spectrum
antivir
activ
address
review
question
whether
two
lipid
inhibit
srebp
activ
evalu
bind
activ
presenc
ficz
respect
shown
two
lipid
like
bind
srebp
inhibit
viru
replic
show
signific
inhibitori
effect
p
result
includ
supplementari
manuscript
yuan
et
al
describ
identif
sterol
regulatori
element
bind
protein
srebp
key
regul
lipid
biosynthesi
potenti
cellular
target
antivir
therapeut
author
use
transcriptom
lipidom
profil
well
multipl
molecular
biochem
method
show
proteolyt
process
lipid
biosynthesi
pathway
includ
palmitoyl
doublemembran
vesicl
format
affect
srebp
latter
known
essenti
viru
replic
particl
format
author
found
previous
establish
compound
block
srebp
bind
sterol
regulatori
element
sre
treatment
post
infect
inhibit
viru
replic
vitro
merscov
sarscov
zikv
vivo
mous
model
merscov
influenza
viru
author
therefor
claim
identifi
broadspectrum
antivir
drug
manuscript
overal
concis
well
written
data
gener
support
vitro
vivo
data
identif
key
regul
lipid
biosynthesi
interest
particular
virus
exploit
pathway
sequest
byproduct
viru
replic
dsrna
immun
recognit
produc
viru
progeni
howev
claim
identifi
broadact
antivir
therapeut
opinion
exagger
neither
appli
organoid
intestin
model
rel
artifici
transgen
mous
model
justifi
titl
paper
ie
target
srebpdepend
lipidom
reprogram
viru
infect
broadspectrum
therapeut
intervent
importantli
offtarget
downstream
effect
result
treatment
investig
particular
lack
dmv
format
may
affect
innat
immun
regul
supplementari
figur
suffici
exclud
affect
immun
regul
context
merscov
replic
respons
thank
insight
comment
review
agre
review
toneddown
titl
srebp
depend
lipidom
reprogram
potenti
broadspectrum
antivir
target
addit
experi
see
respons
show
trigger
respons
addit
merscov
infect
cell
supplementari
note
viru
titrat
plaqu
assay
rtqpcr
method
appli
cultur
supernat
sampl
cell
lysat
sampl
examin
rtqpcr
shown
ad
signific
reduct
plaqu
form
unit
viral
load
especi
vero
cell
use
reduct
measur
plaqu
assay
vs
reduct
measur
rtqpcr
find
line
review
comment
increas
defect
viral
particl
treatment
includ
fig
supplementari
supplementari
inform
page
compound
inhibit
dmv
format
like
result
increas
exposur
merscovderiv
dsrna
cellular
helicas
subsequ
activ
interferon
pathway
pleas
includ
experi
use
viru
infect
treatment
follow
assess
immun
activ
exampl
real
time
pcr
ifn
elisa
respons
investig
possibl
studi
express
merscovinfect
human
monocytederiv
macrophag
mdm
qpcr
elisa
method
presenc
absenc
chose
mdm
key
cell
involv
innat
immun
respons
qpcr
result
normal
mockinfect
group
suggest
addit
virusinfect
cell
lead
increas
antivir
timepoint
postinfect
decreas
proinflammatori
later
timepoint
like
elisa
howev
secret
detect
limit
timepoint
bd
except
observ
elisa
could
explain
antagon
earli
antivir
respons
merscov
zhou
et
al
zielecki
et
al
previou
public
probabl
mediat
viral
structur
accessori
nonstructur
protein
papainlik
proteas
yang
et
al
anoth
report
suggest
proinflammatori
effect
believ
outweigh
antivir
effect
sar
patient
huang
et
al
thu
reduc
product
detect
like
due
decreas
merscov
replic
therefor
believ
inhibit
dmv
format
decreas
shield
dsrna
dmv
lead
increas
innat
immun
respons
ad
respons
agre
review
might
residu
factor
infecti
cell
cultur
supernat
may
disturb
pfu
format
appli
plaqu
assay
howev
dilut
effect
case
lowest
dilut
factor
would
significantli
diminish
interfer
plaqu
assay
also
advis
review
rtqpcr
assay
use
confirm
antivir
activ
shown
supplementari
also
plaqu
assay
parallel
signific
increas
secret
merscov
infect
cell
treatment
see
respons
downstream
effect
disturb
plaqu
format
either
addit
check
thoroughli
made
sure
essenti
detail
ie
timepoint
cell
line
moi
provid
legend
cell
use
highli
permiss
merscov
infect
also
highli
activ
lipid
metabol
ad
viru
entryintern
ie
viruscel
incub
infecti
inoculum
aspir
wash
replac
fresh
medium
contain
pleas
refer
legend
page
line
detail
figur
g
intestin
organoid
interest
model
merscov
obvious
respiratori
viru
human
airway
epitheli
cell
would
appropri
model
case
respons
agre
review
ad
addit
data
term
antimerscov
activ
human
airway
epitheli
cell
found
human
primari
small
airway
epitheli
cell
permiss
merscov
infect
inde
exhibit
substanti
reduct
viru
replic
detect
intracellular
cell
cultur
supernat
pleas
refer
new
fig
legend
page
line
detail
also
mention
primari
cell
methodolog
page
line
minor
figur
respons
pathway
enrich
topolog
result
deriv
integr
transcriptom
lipidom
analysi
metaboanalyst
webserv
target
metabolom
data
analysi
kegg
pathway
enrich
conduct
transcriptom
data
r
packag
clusterprofil
data
sourc
methodolog
background
databas
differ
two
analys
may
lead
differ
result
suppl
fig
gene
enrich
less
whilst
go
enrich
show
enrich
gene
reflect
proport
steroid
biosynthesistot
lipid
biosynthesi
respons
agre
review
gene
go
enrich
repres
differenti
express
gene
deg
includ
go
term
lipid
metabol
around
gene
compil
steroid
biosynthesi
pathway
kegg
databas
howev
reflect
proport
steroid
biosynthesi
among
total
lipid
biosynthesi
due
variat
background
databas
among
differ
analyt
tool
present
stage
find
univers
standard
match
databas
unifi
go
kegg
analysi
tool
therefor
possibl
steroid
biosynthesi
gene
includ
kegg
includ
go
vice
versa
lead
discrep
result
analysi
two
analyt
tool
figur
timepoint
n
protein
detect
explain
kinet
fig
show
timepoint
beyond
hour
hour
wb
show
hour
post
infect
respons
cell
highli
permiss
merscov
infect
thu
differ
timepoint
coupl
differ
multipl
infect
moi
appli
use
low
moi
infect
cell
evalu
antivir
effect
rel
longer
time
interv
high
moi
appli
determin
viral
nprotein
express
accord
observ
cell
start
develop
cytopath
effect
cpe
merscov
infect
hour
high
moi
therefor
select
endpoint
demonstr
similar
level
host
cell
significantli
less
amount
viral
np
protein
specifi
condit
result
descript
page
line
legend
page
line
figur
figur
pleas
also
provid
inform
regard
pfuml
mention
respons
besid
figur
merscov
mous
model
also
provid
viral
load
viral
titer
influenza
mous
model
gener
plaqu
assay
qpcr
result
exhibit
similar
pattern
viru
inhibit
vivo
mention
respons
previou
version
qpcr
result
mous
sampl
move
supplementari
respect
figur
paf
mani
function
includ
cellular
signal
host
defens
inflammatori
respons
includ
paf
one
routin
intern
standard
paf
may
good
repres
lipid
extract
intern
control
end
odd
carbon
chain
glycerophospholipid
standard
pc
pe
pg
might
better
option
refer
lipidmap
http
wwwlipidmapsorg
method
secondli
also
acknowledg
limit
intern
standard
addit
method
discuss
direct
addit
biolog
sampl
lipid
extract
pleas
refer
page
line
final
identif
antivir
compound
pure
serendipit
despit
fact
came
lipid
librari
screen
compound
librari
neither
lipid
bioactiv
fact
long
known
select
agonist
bind
srebp
shown
studi
clearli
demonstr
offtarget
effect
remov
refer
bioactiv
lipid
necessari
offtarget
effect
acknowledg
manuscript
guarante
compound
bind
target
might
come
light
futur
remov
word
bioactiv
page
line
throughout
manuscript
refer
bioactiv
lipid
also
acknowledg
offtarget
effect
page
line
compound
multitarget
binder
due
intrins
structur
featur
